Where does Janssen Pharmaceutica NA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Janssen Pharmaceutica NA ranks #8,844 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Janssen Pharmaceutica NA hold?

Janssen Pharmaceutica NA holds 36 US utility patents granted between 2015 and 2024, spanning 19 technology areas.

What is Janssen Pharmaceutica NA's Innovation Score?

Janssen Pharmaceutica NA has an Innovation Score of 48.5 out of 100 (top 16% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Janssen Pharmaceutica NA focus on?

Janssen Pharmaceutica NA's top technology area is C07D (Heterocyclic Compounds) with 30 patents, ranking #277 of 3,165 assignees active in that subclass. Grants appear in 19 CPC subclasses total.

Is Janssen Pharmaceutica NA's patent grant rate increasing or decreasing?

Janssen Pharmaceutica NA's recent grant velocity is -94% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Janssen Pharmaceutica NA's patents?

Janssen Pharmaceutica NA's patents average 12.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Janssen Pharmaceutica NA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Janssen Pharmaceutica NA

USPTO PatentsView assignee record - 36 granted patents across 19 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Janssen ranks #8,844 of 49,997 tracked US assignees by granted-patent volume, with 36 patents across 19 technology areas.

#8,844
of 49,997 US assignees by volume: Top 16%
by Innovation Score (48.5/100): 12.2
avg claims per patent: -94%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8844 · Foreign Corporation #8,844 · 36 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 36 grants
UPPER-Q #8,844/49,997
PHOTO-FINISH Intellectual…
CPC-FOCUS C07D · 19 areas
INNOV-PAR 48.5/100
CLAIMS-RICH 12.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -94% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Intellectual Property Innovation Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Janssen’s 48.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.5 pts (26%) Velocity 13.3 pts (27%) Breadth 15.4 pts (32%) Claim depth 7.3 pts (15%)

Qualcomm Incorporated · highest

85
Aircelle · near

49
Avecto · near

49
Janssen Pharmaceutic… · this assignee

49
Latency · near

49
SPM Oil & Gas PC · near

49
3D Lighting… · lowest

7

What this shows Janssen's Innovation Score is 48.5/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Janssen?

Each dot is one of Janssen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Janssen’s own 12.2 claims/patent is ABOVE the 9.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Janssen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Janssen's grants concentrate

Janssen Pharmaceutica NA is a focused PatentsView assignee: 19 CPC subclasses with 83.3% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (16 grants) versus a trough of 1 in 2022. By volume, Janssen sits between Intellectual Property Innovation Corporation and Korea Institute OF Oriental Medicine.

Janssen's three-year grant acceleration

Janssen Pharmaceutica NA shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Intellectual Prop…

36
Isolynx

36
JBL International

36
Jinan University

36
Jazz Pharmaceutic…

36
KE COM (Beijing)…

36
Kodiak Networks

36
Korea Institute O…

36
Janssen Pharmaceu… ◀

36

What this shows Janssen holds 36 patents at rank #8,845, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Janssen

By rank, the assignees closest to #8,845 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Janssen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Janssen, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Janssen ranks #277 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (49 here).

Avecto Limited 49 Latency, LLC 49 Aircelle 49 SPM Oil & Gas PC LLC 49

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Janssen Pharmaceutica NA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	16	44.4%
2016	9	25.0%
2017	6	16.7%
2018	3	8.3%
2022	1	2.8%
2024	1	2.8%

Which technologies does Janssen Pharmaceutica NA patent most?

C07D - Heterocyclic Compounds 30

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 30

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 19

C07C - Acyclic OR Carbocyclic Compounds 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

Y02A - Technologies FOR Adaptation TO Climate Change 2

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

G09B - Educational OR Demonstration APPLIANCES; Appliances FOR Teaching, OR Communicating With, THE Blind, Deaf OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; Diagrams 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 1

C10M - Lubricating Compositions ; USE OF Chemical Substances Either Alone OR AS Lubricating Ingredients IN A Lubricating Composition 1

Top 15 of 19 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Janssen Pharmaceutica NA's patent record in context - here's where to go next.

Janssen Pharmaceutica NA's lead technology class is C07D (Heterocyclic Compounds), 83.3% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #8,844 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Janssen Pharmaceutica NA against Intellectual Property Innovation Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.